



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Editorial Officer
✉ research.integrity@frontiersin.org

RECEIVED 12 February 2025
ACCEPTED 12 February 2025
PUBLISHED 26 February 2025

CITATION
Frontiers Editorial Office (2025) Retraction:
Upregulation of CCT-3 induces
breast cancer cell proliferation through
miR-223 competition and Wnt/ β -catenin
signaling pathway activation.
Front. Oncol. 15:1575634.
doi: 10.3389/fonc.2025.1575634

COPYRIGHT
© 2025 Frontiers Editorial Office. This is an
open-access article distributed under the terms
of the [Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Retraction: Upregulation of CCT-3 induces breast cancer cell proliferation through miR-223 competition and Wnt/ β -catenin signaling pathway activation

Frontiers Editorial Office*

A Retraction of the Original Research Article

[Upregulation of CCT-3 induces breast cancer cell proliferation through miR-223 competition and Wnt/ \$\beta\$ -catenin signaling pathway activation](#)

By Qu H, Zhu F, Dong H, Hu X and Han M (2020) *Front. Oncol.* 10:533176. doi: 10.3389/fonc.2020.533176

The publisher retracts the 24 September 2020 article cited above.

Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide the raw data or a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers' policies. Given the concerns about the validity of the data, and the lack of raw data, the editors no longer have confidence in the findings presented in the article.

This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors received a communication regarding the retraction and had a chance to respond. This communication has been recorded by the publisher.

Frontiers would like to thank the users on PubPeer for bringing the published article to our attention.